Eliquis (apixaban) available at more than 40 per cent discount; Sotyktu to be offered at more than 80 per cent discount to current list price
Both of Moderna's COVID-19 vaccines for the 2025-2026 season have demonstrated strong immune responses against today's top circulating COVID-19 strains
Represents one of the largest cell culture biomanufacturing sites in North America, which will employ 1,400 people by 2031
_LOGO_256_384.jpg){kind=logo}
The association called for an end to the constant issuance of regulatory circulars that make operations unpredictable and capital-intensive.
All drug substance for Moderna’s authorized Spikevax (COVID-19 mRNA vaccine) targeting the SARS-CoV-2 LP.8.1 variant is produced at the company’s facility in Laval, Quebec
Conducted entirely in Europe across forty sites in five countries, this rigorous study met all clinical endpoints
IND application for EB-003 expected in early 2026
Includes new $1.2 billion investment in manufacturing facilities, AI and advanced digital technologies, creating hundreds of highly skilled U.S. jobs
A new medical-grade Amodel PPA delivers high heat resistance, electrically insulative properties, and biocompatibility for advanced single-use medical instruments and assemblies
Ascletis announces ultra-long-acting subcutaneous depot maintenance formulation of small molecule GLP-1R agonist ASC30 with 75-Day observed half-life in participants with obesity
Subscribe To Our Newsletter & Stay Updated
